Fisher Releases Perspective on Pharmaceutical Stocks

    WOODSIDE, CA, September 14, 2011 /24-7PressRelease/ -- Fisher Investments released a new research brief discussing major drivers of pharmaceutical stocks, entitled Two Drivers for Pharmaceutical Stocks. Fisher provides commentary on the global Pharmaceutical industry and the illustrious fears of the "patent cliff."

The piece delves into two drivers affecting Pharmaceutical stocks. The first is upcoming patent expirations and their projected impact on annual sales between 2010 and 2020. The second driver Fisher Investments analyzes is equally important but lesser-known: positive pipeline developments--mainly New Molecular Entity (NME) approvals and their potential to drive up sales and pricing power for Pharmaceutical firms.

In its discussion of what challenges face the Pharmaceutical industry, this new piece explains, "While the patent cliff is a challenge the Pharmaceutical industry must navigate in the coming years, it's important to place it in context with other drivers. This widely publicized concern eases in two years and, balanced against NME approvals, likely isn't as large a negative as many presume, in our view. Weighing these two drivers in the Pharmaceutical industry seems to indicate a brighter outlook than valuations currently reflect."

The full document, which comprehensively explores the previewed topics, can be found at Fisher Investments' website: http://fisherinvestments.bo.lt/pharma.

About Fisher Investments

Founded in 1979, Fisher Investments is an independent, privately-owned money management firm with more than $44 billion (as of 6/30/11) under management. Fisher Investments maintains two principal business units, Fisher Investments Institutional Group and Fisher Investments Private Client Group, which serve a global client base of diverse investors. Fisher Investments' clients include over 100 large institutions and over 25,000 high net worth individuals. Founder and CEO Ken Fisher has written the Forbes "Portfolio Strategy" column for 26 years, has written 7 books on investing and personal finance (4 of which are bestsellers), and was recently named by Investment Advisor magazine as one of the 30 most influential industry individuals in the last 30 years (Thirty for Thirty, May 2010). For more information visit http://www.fisherinvestments.com/.

# # #